Inhibitors of glucosylceramide synthase.
Shayman
J A
JA
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0676, USA.
Lee
L
L
Abe
A
A
Shu
L
L
D002455:Cell Division / Q000187:drug effects; D002518:Ceramides / Q000096:biosynthesis; D004337:Drug Carriers; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005963:Glucosylceramides / Q000096:biosynthesis*; D005964:Glucosyltransferases / Q000037:antagonists & inhibitors*; D006028:Glycosphingolipids / Q000096:biosynthesis; D009025:Morpholines / Q000138:chemical synthesis / Q000737:chemistry*; D011412:Propanolamines / Q000138:chemical synthesis; D011759:Pyrrolidines / Q000138:chemical synthesis; D013107:Sphingolipids / Q000096:biosynthesis / Q000138:chemical synthesis; D013237:Stereoisomerism
C095823:1-phenyl-2-palmitoylamino-3-morpholino-1-propanol; C401299:1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol; D002518:Ceramides; D004337:Drug Carriers; D004791:Enzyme Inhibitors; D005963:Glucosylceramides; D006028:Glycosphingolipids; D009025:Morpholines; D011412:Propanolamines; D011759:Pyrrolidines; D013107:Sphingolipids; C033110:RV 538; D005964:Glucosyltransferases; C023246:ceramide glucosyltransferase